Blog Posts
HARMONi-A

Hidehito Horinouchi: HARMONi-A – Chemo +/- Ivonescimab in EGFRm NSCLC after EGFR-TKIs resistance

Hidehito Horinouchi, Oncologist at the Department of Thoracic Oncology at the National Cancer Center Hospital, recently shared a post on X:

“ASCO24 Abstracts

No. 8508 HARMONi-A: Chemo +/- Ivonescimab (AK112/SMT112, anti-PD-1/VEGF bispecific ab) in EGFRm NSCLC after EGFR-TKIs resistance
Presenter: Dr. Li Zhang

  • PFS HR 0.46 (95%CI: 0.34, 0.62),
  • Phase III,
  • Primary PFS,
  • NCT05184712.”

Source: Hidehito Horinouchi/X

ASCO24 cancer EGFR mutation in NSCLC HARMONi-A trial Hidehito Horinouchi ivonescimab Li Zhang National Cancer Center Hospital NSCLC OncoDaily Oncology